Print Page  Close Window

Investor Center Home
Corporate Profile
Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders.

More >>

BLCM (Common Stock)
(US Dollar)
(%)Volume (0.00%)0
Data as of 10/19/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
08/30/17Bellicum Pharmaceuticals to Present at Three Healthcare Investor Conferences in SeptemberPrinter Friendly Version
08/08/17Bellicum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate UpdatePrinter Friendly Version
08/03/17Bellicum Pharmaceuticals Appoints Gregory Naeve as Chief Business OfficerPrinter Friendly Version
08/01/17Bellicum Pharmaceuticals to Report Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 8, 2017Printer Friendly Version
More >>
Upcoming Events
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources